LABFF (Laboratorios Farmaceuticos Rovi) 10-Year Share Buyback Ratio: -0.30% (As of Mar. 2026)


LABFF Laboratorios Farmaceuticos Rovi SA LABFF
93 GF Score
Price $90.61
GF Value $82.42
! 1 Warning Sign
View Full Analysis

What is Laboratorios Farmaceuticos Rovi 10-Year Share Buyback Ratio?

Laboratorios Farmaceuticos Rovi LABFF 93 10-Year Share Buyback Ratio is -0.30 as of Mar. 2026. GuruFocus rates LABFF with a GF Score™ of 93/100 and a GF Value™ of $82.42. The stock has 1 warning sign investors should review. Among 624 Drug Manufacturers companies, Laboratorios Farmaceuticos Rovi ranks better than 74.04% on this metric.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Laboratorios Farmaceuticos Rovi's current 10-Year Share Buyback Ratio was -0.30%.

LABFF's 10-Year Share Buyback Ratio is ranked better than
74.04% of 624 companies
in the Drug Manufacturers industry
Industry Median: -2.1 vs LABFF: -0.30

Laboratorios Farmaceuticos Rovi (OTCPK:LABFF) 10-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.


Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.


Laboratorios Farmaceuticos Rovi 10-Year Share Buyback Ratio Related Terms


LABFF vs ZTS, UTHR, VTRS: 10-Year Share Buyback Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorios Farmaceuticos Rovi's 10-Year Share Buyback Ratio, along with its competitors' market caps and 10-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Laboratorios Farmaceuticos Rovi 10-Year Share Buyback Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's 10-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Laboratorios Farmaceuticos Rovi's 10-Year Share Buyback Ratio falls into.


LABFF
93GF Score
Laboratorios Farmaceuticos Rovi SA LABFF
10-Year Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Laboratorios Farmaceuticos Rovi 10-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from ten years ago to the current year. The annualized percentage change is calculated with least-square regression based on the eleven years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

What does a 10-Year Share Buyback Ratio of -0.30 mean?
Laboratorios Farmaceuticos Rovi (LABFF) has a 10-Year Share Buyback Ratio of -0.30 as of Mar. 2026. The 10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. View historical data for Laboratorios Farmaceuticos Rovi and its competitors. According to the industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #162 out of 624 companies in the Drug Manufacturers industry, placing it in the top 26%.
Is Laboratorios Farmaceuticos Rovi's 10-Year Share Buyback Ratio too high?
Laboratorios Farmaceuticos Rovi's current 10-Year Share Buyback Ratio is -0.30. Based on the distribution chart, Laboratorios Farmaceuticos Rovi ranks #162 out of 624 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's 10-Year Share Buyback Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #162 out of 624 companies for 10-Year Share Buyback Ratio. This puts Laboratorios Farmaceuticos Rovi in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year Share Buyback Ratio for a Drug Manufacturers company?
A good 10-Year Share Buyback Ratio depends on the Drug Manufacturers industry context. However, 10-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year Share Buyback Ratio mean?
A high 10-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. View historical data for Laboratorios Farmaceuticos Rovi and its competitors. Laboratorios Farmaceuticos Rovi's current 10-Year Share Buyback Ratio is -0.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Laboratorios Farmaceuticos Rovi (LABFF) has a current 10-Year Share Buyback Ratio of -0.30. The stock's GF Value™ is $82.42, compared to a current price of $90.61 — trading 9.9% above its estimated fair value. The current 10-Year Share Buyback Ratio is -0.30. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 93/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year Share Buyback Ratio calculated?
10-Year Share Buyback Ratio is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (LABFF), the current 10-Year Share Buyback Ratio is -0.30 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Laboratorios Farmaceuticos Rovi (LABFF) Overvalued in 2026?

Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be overvalued. The current stock price of $90.61 is trading 9.9% above its estimated GF Value™ of $82.42.

Key valuation signals for LABFF:

  • 10-Year Share Buyback Ratio: -0.30
  • GF Value™: $82.42 vs. price of $90.61 (9.9% above fair value)
  • GF Score™: 93/100 with 1 warning sign

No single metric tells the full story. See the LABFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Laboratorios Farmaceuticos Rovi Business Description

Address Julian Camarillo, 35, Madrid, ESP, 28037
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
93GF Score

Get the complete analysis for LABFF

10-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$90.61
Price
$82.42
GF Value